Bristol Myers Squibb stock gains on Q2 beat and raised 2026 guidance
Published on 09/04/2026 at 07:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock (ISIN US0897961004) is benefiting from a stronger fundamental backdrop after the pharma group reported Q2 2026 revenue of 12.97 billion USD and adjusted EPS of 2.04 USD, both above market expectations, as of the quarterly update reported on July 30, 2026 according to Yahoo Finance.
Q2 2026 results support a higher outlook
According to the same Q2 2026 report, Bristol Myers Squibb increased its full-year 2026 revenue guidance to a range of 49 billion USD to 50 billion USD, up from its previous outlook, and lifted adjusted EPS guidance to 6.75 USD to 7.00 USD, signaling confidence in the earnings trajectory.
In Q2 2026, Eliquis revenue rose 22 percent to 4.48 billion USD, and management raised the full-year Eliquis growth forecast to a range of 20 percent to 25 percent, highlighting how demand for the blockbuster blood thinner is still expanding strongly compared with the prior year, based on figures compiled by Yahoo Finance.
Growth portfolio offsets pressure on legacy drugs
The same Q2 2026 analysis notes that Bristol Myers Squibb's growth portfolio of newer medicines expanded revenue by 15 percent year over year, driven by therapies such as Reblozyl, Camzyos and Breyanzi, which all surpassed sales expectations in the quarter according to Yahoo Finance.
At the same time, the company continues to face headwinds from older products, with revenue from Revlimid declining in Q2 2026 as generic competition builds; the ability of the newer portfolio to deliver double-digit growth is therefore crucial for maintaining overall top-line expansion relative to Q2 2025, as highlighted in the same coverage.
More on Bristol Myers Squibb fundamentals
Investors who want to track Bristol Myers Squibb stock beyond the latest Q2 2026 figures can find additional news and financial information in the dedicated topic and investor sections.
Key product focus: Eliquis and newer therapies
For Bristol Myers Squibb, Eliquis remains the largest single product contributor, with Q2 2026 sales of 4.48 billion USD representing a substantial share of group revenue and growing more than one fifth year over year, based on data reported by Yahoo Finance.
Stock performance and valuation context
According to market data compiled by MarketBeat, Bristol Myers Squibb stock traded at 53.93 USD at the beginning of 2026 and has since climbed to around 67.55 USD, marking a gain of about 25.3 percent year to date as of early September 2026, which places the shares closer to the upper end of their recent trading range.
Bristol Myers Squibb stock facts
- Company: Bristol Myers Squibb Co.
- ISIN: US0897961004
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 3, 2026): 67.55 USD
- Market capitalization: 140,000,000,000 USD (as of September 3, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
